SPRINTER: Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
Study Details
Study Description
Brief Summary
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: SNG001 SNG001 via inhalation using Ultra device, once a day for 14 days |
Drug: SNG001
SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
|
| Placebo Comparator: Placebo Placebo via inhalation using Ultra device, once a day for 14 days |
Drug: Placebo
Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
|
Outcome Measures
Primary Outcome Measures
- Time to hospital discharge [Day 1 until Day 28]
To evaluate the time to hospital discharge in patients with moderate COVID-19 after administration of SNG001 compared to placebo. Here, hospital discharge can be considered when World Health Organization (WHO) Ordinal Scale for Clinical Improvement (OSCI) score of 2 (limitation of activities) or below, with no rebound at subsequent assessments. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.
- Time to recovery [Day 1 until Day 28]
To evaluate recovery in patients with moderate COVID-19 after administration of SNG001 compared to placebo by time to recovery. Here, recovery is defined as the WHO OSCI score of 1 (no limitation of activities) or below, with no rebound at subsequent assessments. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.
Secondary Outcome Measures
- Progression to severe disease or death [Day 1 until Day 35 or randomisation date if the patient is not dosed]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to severe disease or death. Progression to severe disease or death is defined by the WHO OSCI score of 5 (non-invasive ventilation or high-flow oxygen) or above within 35 days of first dose. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death. This is a key secondary endpoint.
- Progression to intubation or death [Day 1 until Day 35 or randomisation date if the patient is not dosed]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to intubation or death. Here, progression to intubation or death defined by the WHO OSCI score of 6 (intubation and mechanical ventilation) or above within 35 days of first dose. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death. This is a key secondary endpoint.
- Death within 35 days of first dose [Day 1 until Day 35 or randomisation date if the patient is not dosed]
Death within 35 days of first dose, defined by the WHO OSCI score of 8 (death). This is a key secondary endpoint.
- Recovery as analysed at Days 7, 14, 21 and 28 [Days 7, 14, 21 and 28]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing recovery. Recovery is defined as the WHO OSCI score of 1 (no limitation of activities) or below, with no rebound at subsequent assessments. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.
- Hospital discharge by days 7, 14, 21 and 28 [Days 7, 14, 21 and 28]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing hospital discharge on given days.
- Number of patients with improvement based on entire WHO OSCI score by days 7, 14, 21 and 28 [Days 7, 14, 21 and 28]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing improvement across the entire WHO OSCI. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.Higher scores indicated worse outcome.
- Change in total score according to the breathlessness, cough and sputum scale (BCSS) and disaggregated breathlessness and cough scores [Day 1 until Day 28 and then on Day 60 and Day 90]
To evaluate the efficacy of SNG001 compared with placebo in patients with moderate COVID-19 by assessing changes in daily breathlessness, cough and sputum scores on a scale of 0 (no symptoms) up to 4 (severe symptoms)
- Changes in National Early Warning Score (NEWS2) during the hospitalisation period [Day 1 until Day 28]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing changes in NEWS2 during hospitalisation period. The NEWS2 is a tool which is used in detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes. Six physiological parameters such as: respiration rate, oxygen saturation, any supplementary oxygen, temperature, systolic blood pressure, heart rate, and alert, voice, pain, and unresponsive form the basis of the scoring system.
- Number of patients with presence of COVID-19 symptoms based on daily assessment [Day 1 until Day 28]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of COVID-19 symptoms. The presence of COVID-19 symptoms will be assessed. Individual symptoms related to COVID-19/SARS-CoV-2 infection such as fever, breathlessness, and fatigue will be assessed.
- Number of patients with limitations of usual activities based on daily assessment [Day 1 until Day 28]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of limitation of usual activities. The patients with limitations of usual activities will be patients who are unable to do usual activities (work, study, housework, family or leisure activities).
- Quality of life measured using EuroQol 5-dimension 5-level (EQ-5D-5L) [Day 0, Day 7, Day 15, Day 28, Day 60 and Day 90; Day 1 until Day 35 (mobility, self care and usual activities dimension)]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by using EQ-5D-5L. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health. The mobility, self-care and usual activities dimensions of the questionnaire will be assessed daily from Day 1 to Day 35.
- Number of patients with long-COVID-19 symptoms based on General Anxiety Disorder 7 Questionnaire (GAD-7) [Day 15, Day 28, Day 60 and Day 90]
To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing long-COVID-19 symptoms. Assessment of long-COVID-19 symptoms based on GAD-7. Scoring will be done based on how often patients have been bothered by the problems as: feeling nervous, anxious or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it's hard to sit still; becoming easily annoyed or irritable, and feeling afraid at if something awful might happen. The scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.
- Number of patients with long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4) [Day 15, Day 28, Day 60 and Day 90]
Assessment of long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4). The FACIT Fatigue Scale (Version 4) will include statements for patients such as: I feel fatigued; I feel weak all over; I feel listless ("washed out"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Higher scores indicated worse outcome.
- Number of patients with long-COVID-19 symptoms based on Patient Health Questionnaire-9 (PHQ-9) [Day 15, Day 28, Day 60 and Day 90]
Assessment of long-COVID-19 symptoms based on PHQ-9. Patient health questionnaire included: little interest or pleasure in doing things; feeling down, depressed, or hopeless; trouble falling asleep or staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself - or that you are a failure of have let yourself or your family down; trouble concentrating on things, such as reading the newspaper or watching television; moving or speaking so slowly that other people could have noticed or so fidgety or restless that you have been moving a lot more than usual; and thoughts that you would be better off dead; or thoughts of hurting yourself in some way. Based on responses on questionnaire, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.
- Number of patients with long-COVID-19 symptoms based on Brief Pain Inventory (Short Form) [Day 15, Day 28, Day 60 and Day 90]
Assessment of long-COVID-19 symptoms based on brief pain inventory form. Form include questionnaires as: did patient had pain other than everyday kinds of pain on assessment day; body part where patient feels pain; rate patient's pain: at worst, at least in the last 24 hours, at average, and at right now, by giving scores from 0 to 10, where 0 indicates no pain and 10 represents pain as bad as one can imagine; treatments or medications receiving for pain by patients; rate how much relief have pain treatments have provided from 0% to 100%, where 0% represents no relief and 100% indicates complete relief; assessment of interference of pain in following patients activity: general activity; mood; walking ability; normal work; relations with other people; sleep; enjoyment of life, and assessment will be done by scoring and scores ranges from 0 to 10, where 0 represents pain does not interfere and 10 indicates pain completely interferes in above activity.
- Number of patients with adverse events (AEs) and serious adverse events (SAEs) [Day 1 until Day 28]
To assess the general safety and tolerability of SNG001 compared to placebo when administered to patients with moderate COVID-19 by assessing number of patients with AEs.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Admitted to hospital due to the severity of their COVID-19
-
Positive virus test for SARS-CoV-2 using a validated molecular assay or antigen assay. Patients who had a positive virus test for SARS-CoV-2 prior to hospitalisation will be randomised no later than 48 hours after hospital admission. If the virus test is performed more than 96 hours prior to hospitalisation, the test will have to be repeated in the hospital prior to randomisation. Only patients whose repeated virus test is positive will be randomised, no later than 48 hours after confirmation of SARS-CoV-2 infection. Patients who had their first positive virus test for SARS-CoV-2 after hospitalisation will be randomised no later than 48 hours after confirmation of SARS-CoV-2 infection
-
Require oxygen therapy via nasal prongs or mask (WHO OSCI score of 4)
-
Provided informed consent
-
Female patients must be ≥1 year post-menopausal, surgically sterile, or using a protocol defined highly effective method of contraception
-
Women of child bearing potential should have been stable on their chosen method of birth control for a minimum of 3 months before entering the trial and should continue with birth control for 1 month after the last dose of inhaled interferon-β (IFN-β1a)/matching placebo. In addition to the highly effective method of contraception (except for the practice of total sexual abstinence), a condom (in United Kingdom with spermicides) should be used by the male partner for sexual intercourse from randomisation (Visit 2) and for 1 month after the last dose of inhaled IFN-β1a/matching placebo to prevent pregnancy
-
Women not of childbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomisation without an alternative medical cause. The following age specific requirements apply: women <50 years old will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and if follicle stimulating hormone (FSH) levels are in the postmenopausal range; women ≥50 years old will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment. If, in the setting of the pandemic, the use of an acceptable birth control method is not possible, the decision to enrol a woman of childbearing potential should be based on the benefit-risk for the patient, which should be discussed with the patient at the time of the informed consent.
Exclusion Criteria:
-
Evidence of ongoing SARS-CoV-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay
-
Non-invasive ventilation continuous positive airway pressure/bilevel positive airway pressure (CPAP/BiPAP) or high-flow nasal oxygen therapy (WHO OSCI score of 5)
-
Endotracheal intubation and invasive mechanical ventilation (WHO OSCI score of ≥6) or admission to intensive care
-
Previous SARS-CoV-2 infection confirmed by a validated molecular assay or validated antigen assay
-
Any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation
-
Participation in previous clinical trials of SNG001
-
Current or previous participation in another clinical trial where the patient has received a dose of an Investigational Medicinal Product containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study
-
Inability to use a nebuliser with a mouthpiece
-
Inability to comply with the requirements for storage conditions of study medication in the home setting
-
History of hypersensitivity to natural or recombinant IFN-β or to any of the excipients in the drug preparation
-
Females who are breast-feeding, lactating, pregnant or intending to become pregnant.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The University of Arizona Medi | Tucson | Arizona | United States | 85724 |
| 2 | Professional Health Care of Pi | Saint Petersburg | Florida | United States | 33713 |
| 3 | Henry Ford Health System | Detroit | Michigan | United States | 48202 |
| 4 | University of Minnesota | Minneapolis | Minnesota | United States | 55455 |
| 5 | Icahn School of Medicine at Mo | New York | New York | United States | 10029-6500 |
| 6 | PharmaTex Research, LLC | Amarillo | Texas | United States | 79109 |
| 7 | Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich | Ciudad Autónoma De Buenos Air | Buenos Aires | Argentina | C1426BOR |
| 8 | Hospital Universitario Austral | Buenos Aires | Argentina | B1629ODT | |
| 9 | Hospital Papa Francisco - Hosp | Salta | Argentina | 4400 | |
| 10 | AZ Groeninge | Kortrijk | West-Vlaanderen | Belgium | 8500 |
| 11 | UZ Brussel - Campus Jette - In | Brussel | Belgium | 1090 | |
| 12 | Centre Hospitalier Universitai | Bruxelles | Belgium | 1020 | |
| 13 | CHR de la Citadelle - Site Cit | Liège | Belgium | 4000 | |
| 14 | CHU de Liège - Domaine Univers | Liège | Belgium | 4000 | |
| 15 | Instituto Mederi de Pesquisa e Saúde | Passo Fundo | Rio Grande Do Sul | Brazil | 99010-120 |
| 16 | Hospital Moinhos de Vento | Porto Alegre | Rio Grande Do Sul | Brazil | 90035-001 |
| 17 | Clínica SUPERA | Chapeco | Santa Catarina | Brazil | 89801-355 |
| 18 | Sociedade Literaria e Caritativa Santo Agostinho | Criciúma | Santa Catarina | Brazil | 88801-508 |
| 19 | Instituto de Pesquisa Clínica | Campinas | São Paulo | Brazil | 13060-080 |
| 20 | Fundacao Faculdade Regional de | São José do Rio Preto | São Paulo | Brazil | 15090-000 |
| 21 | Clinica de la Mujer | Bogotá | Cundinamarca | Colombia | |
| 22 | FOSCAL | Bucaramanga | Santander | Colombia | 681004 |
| 23 | Clinica de la Costa | Barranquilla | Colombia | ||
| 24 | CHU De Nantes - Infectious Dis | Nantes | Loire-Atlantique | France | 44093 |
| 25 | CHU d'Angers | Angers | Pays-de-la-Loire | France | 49933 |
| 26 | CHU de Grenoble - Hôpital Albe | La Tronche | France | 38700 | |
| 27 | CHU Saint Antoine - Infectious | Paris | France | 75012 | |
| 28 | Hôpital Européen Georges-Pompi | Paris | France | 75015 | |
| 29 | Hopital Bichat - Infectious Di | Paris | France | 75018 | |
| 30 | RoMed Medical Center Rosenheim | Rosenheim | Bayern | Germany | 83022 |
| 31 | Universitätsklinikum Mannheim | Mannheim | Germany | 68167 | |
| 32 | Krankenhaus Bethanien gGmbH | Solingen | Germany | 42699 | |
| 33 | King George Hospital | Visakhapatnam | Andhra Pradesh | India | 530002 |
| 34 | Unity Hospital | Surat | Gujarat | India | 395010 |
| 35 | Rhythm Heart Institute | Vadodara | Gujarat | India | 390022 |
| 36 | Bangalore Medical College and Research Institute | Bangalore | Karnataka | India | 560002 |
| 37 | MS Ramaiah Medical College and Hospital | Bangalore | Karnataka | India | 560054 |
| 38 | Oriion Citicare Super Speciality Hospital - Intern | Aurangabad | Maharashtra | India | 431005 |
| 39 | Fortis Hospital Mulund - Inter | Mumbai | Maharashtra | India | 400078 |
| 40 | Government Medical College Nag | Nagpur | Maharashtra | India | 440003 |
| 41 | Suyog Hospital | Nashik | Maharashtra | India | 422003 |
| 42 | Vishwa Raj Hospital | Pune | Maharashtra | India | 412201 |
| 43 | Acharya Vinoba Bhave Rural Hos | Wardha | Maharashtra | India | 442004 |
| 44 | Post Graduate Institute of Medical Education & Research, Chandigarh | Chandigarh | Punjab | India | 160012 |
| 45 | Saveetha Medical College & Hospital | Chennai | India | 602105 | |
| 46 | Assuta Ashdod University Hospi | Ashdod | HaDarom | Israel | 7747629 |
| 47 | Rambam Health Care Campus | Haifa | Israel | 3109601 | |
| 48 | Ziv Medical Center | Safed | Israel | 131001 | |
| 49 | The Chaim Sheba Medical Center | Tel Hashomer | Israel | 5265601 | |
| 50 | Sourasky Tel Aviv Medical Cent | Tel-Aviv | Israel | 6423906 | |
| 51 | Assaf Harofeh Medical Center | Zerifin | Israel | 7030000 | |
| 52 | Azienda Socio Sanitaria Territ | Monza | Lombardia | Italy | 20900 |
| 53 | Azienda Ospedaliera Nazionale | Alessandria | Italy | 15100 | |
| 54 | PO A.Manzoni di Lecco, ASST Le | Lecco | Italy | 23900 | |
| 55 | Ospedale Luigi Sacco, AO-PU | Milano | Italy | 20157 | |
| 56 | Azienda Ospedaliera Ospedale N | Milano | Italy | 20162 | |
| 57 | AOU Federico II - Malattie Inf | Napoli | Italy | 80131 | |
| 58 | IRCCS Policlinico San Matteo | Pavia | Italy | 27100 | |
| 59 | AOU Pisana | Pisa | Italy | 54124 | |
| 60 | Città della Salute e della Scienza | Torino | Italy | 10139 | |
| 61 | Fundación Santos y de la Garza Evia, I.B.P | Monterrey | Nuevo León | Mexico | 64710 |
| 62 | Hospital General de Culiacan D | Culiacan | Sinaloa | Mexico | 80230 |
| 63 | EME RED Hospitalaria - COVID-1 | Merida | Yucatán | Mexico | 97000 |
| 64 | Hospital General Regional O´Hu | Merida | Yucatán | Mexico | 97000 |
| 65 | Clínica Sociedad Española de Beneficencia | Veracruz | Mexico | 91700 | |
| 66 | Ziekenhuis St Jansdal | Harderwijk | Gelderland | Netherlands | 3844 DG |
| 67 | Gelre Ziekenhuis Zutphen | Zutphen | Gelderland | Netherlands | 7207 AE |
| 68 | Isala Klinieken | Zwolle | Overijssel | Netherlands | 8025 AB |
| 69 | Hospital Garcia da Orta, E.P.E | Almada | Lisboa | Portugal | 2805-267 |
| 70 | C.H. de Vila Nova de Gaia/Espi | Vila Nova de Gaia | Porto | Portugal | 4434-502 |
| 71 | Hospital de Braga | Braga | Portugal | 4710-243 | |
| 72 | Hospital da Senhora de Oliveir | Guimarães | Portugal | 4835-044 | |
| 73 | Centro Hospitalar de Entre Dou | Rodrigues | Portugal | 4520-211 | |
| 74 | Sp. Clinic Boli Infectioase si | Timisoara | Timis | Romania | 300310 |
| 75 | Spitalul Universitar de Urgent | Bucuresti | Romania | 011461 | |
| 76 | Sp. Cl. de Boli Infectioase si | Bucuresti | Romania | 030303 | |
| 77 | Spitalul Clinic de Boli Infect | Craiova | Romania | 200446 | |
| 78 | Clinical Center Nis | Nis | Nišavski Okrug | Serbia | 18000 |
| 79 | Clinical Center of Vojvodina | Novi Sad | Vojvodina | Serbia | 21000 |
| 80 | University Clinical Center of Serbia | Belgrade | Serbia | 11000 | |
| 81 | Clinical Center Kragujevac, Cl | Kragujevac | Serbia | 34000 | |
| 82 | The Institute for Pulmonary Di | Sremska Kamenica | Serbia | 21204 | |
| 83 | CHU A Coruña | Madrid | A Coruña | Spain | 15006 |
| 84 | Hospital Universitario Son Esp | Palma De Mallorca | Baleares | Spain | 7120 |
| 85 | Hospital Universitario Mutua d | Terrassa | Barcelona | Spain | 08221 |
| 86 | Hospital Universitario de Puer | Puerto Real | Cádiz | Spain | 11510 |
| 87 | Hospital Santa Creu i Sant Pau | Barcelona | Spain | 08041 | |
| 88 | Hospital Universitario Infanta | Madrid | Spain | 28031 | |
| 89 | Hospital Universitario Ramón y | Madrid | Spain | 28034 | |
| 90 | H.Clinico San Carlos | Madrid | Spain | 28040 | |
| 91 | Hospital Universitario de Sala | Salamanca | Spain | 37007 | |
| 92 | H U Nuesta Señora de Valme - I | Sevilla | Spain | ||
| 93 | Wexham Park Hospital | Slough | Bracknell Forest | United Kingdom | SL2 4HL |
| 94 | Hull Royal Infirmary | Hull, North Humberside | East Riding Of Yorkshire | United Kingdom | HU3 2RW |
| 95 | Newcastle University - Institute of Cellular Medicine (ICM) | Newcastle | England | United Kingdom | NE2 4HH |
| 96 | Southampton General Hospital | Southampton | Hampshire | United Kingdom | SO16 6YD |
| 97 | Churchill Hospital | Headington | Oxfordshire | United Kingdom | OX3 9DU |
| 98 | Frimley Park Hospital | Frimley | Surrey | United Kingdom | GU16 7UJ |
| 99 | Queen Elizabeth Hospital Birmingham | Birmingham | United Kingdom | B15 2TH | |
| 100 | The Royal Bournemouth & Christ | Bournemouth | United Kingdom | BH7 7DP | |
| 101 | University Hospital of North D | Durham | United Kingdom | DH1 5TW | |
| 102 | Royal Devon & Exeter Hospital | Exeter | United Kingdom | EX25DW | |
| 103 | Glasgow Royal Infirmary | Glasgow | United Kingdom | G4 0SF | |
| 104 | Glenfield Hospital | Leicester | United Kingdom | LE3 9QP | |
| 105 | University Hospital Lewisham | London | United Kingdom | SE13 6LH | |
| 106 | Guy's Hospital | London | United Kingdom | SE19RT | |
| 107 | North Manchester General Hospi | Manchester | United Kingdom | M8 5RB | |
| 108 | The James Cook University Hosp | Middlesbrough | United Kingdom | TS4 3BW | |
| 109 | Nottingham University Hospital | Nottingham | United Kingdom | NG51PB | |
| 110 | Plymouth Hospitals NHS Trust | Plymouth | United Kingdom | PL6 8DH | |
| 111 | Morriston Hospital Swansea NHS | Swansea | United Kingdom | SA6 6NL | |
| 112 | University Hospital of Wales | Swansea | United Kingdom | SA6 6NL |
Sponsors and Collaborators
- Synairgen Research Ltd.
Investigators
- Principal Investigator: Professor Tom Wilkinson, University Hospital Southampton NHS Foundation Trust
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SG018
- 2020-004743-83